

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61K 31/445, 9/20</b>		A1	(11) International Publication Number: <b>WO 95/16448</b> (43) International Publication Date: <b>22 June 1995 (22.06.95)</b>
(21) International Application Number: <b>PCT/EP94/04164</b> (22) International Filing Date: <b>14 December 1994 (14.12.94)</b>  (30) Priority Data: <b>9325644.4 15 December 1993 (15.12.93) GB</b>		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).  Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant ( <i>for all designated States except US</i> ): <b>SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</b>  (72) Inventors; and (75) Inventors/Applicants ( <i>for US only</i> ): <b>PATHAK, Ram, Dutta [GB/GB]; SmithKline Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). DOUGHTY, David, George [GB/GB]; SmithKline Beecham Pharmaceuticals, Mundells, Welwyn Garden City, Hertfordshire AL7 1EY (GB).</b>  (74) Agent: <b>RUSSELL, Brian, J.; Smithkline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).</b>			
(54) Title: <b>PAROXETINE TABLETS AND PROCESS TO PREPARE THEM</b>			
(57) Abstract <p>Paroxetine which is formulated into tablets using a formulation process in which water is absent.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Paroxetine tablets and process to prepare them

The present invention relates to novel formulations and to the use of the formulation in the treatment and/or prevention of certain disorders.

- 5 US Patent 4,007,196 describes certain compounds which possess anti-depressant activity. One specific compound mentioned in this patent is known as paroxetine and which has the following formula:



10

This compound has been approved for human use and is being sold in many countries around the world as an anti-depressant agent.

It has been noticed that tablets of paroxetine often develop a pink hue which is highly undesirable.

- 15 To date, all tablets which have been sold have been formulated using an aqueous granulation process. It has surprisingly been found that formulation of paroxetine into tablets can be carried out reliably and on a commercial scale using a formulation process in which water is absent, such as by direct compression or by dry granulation.

- 20 It has also been surprisingly found that paroxetine formulated into a tablet using a process in which water is absent, is much less likely to develop a pink hue.

Accordingly, the present invention provides paroxetine which is formulated into tablets using a formulation process in which water is absent.

- 25 Examples of such a formulation process are dry direct compression of paroxetine or dry granulation of paroxetine followed by compression into tablets. The present invention therefore provides a formulation comprising direct compressed paroxetine admixed with dry excipients in the form of a tablet and a formulation comprising dry granulated and compressed paroxetine admixed with dry excipients in the form of a tablet.

- 30 It should be appreciated that the term "dry" means substantially "dry" as opposed to the wholesale addition of water which was previously employed in the wet granulation process.

Direct compression techniques are generally known in the art of pharmaceutical science. For example, paroxetine is conventionally admixed with dry excipients and compressed into tablets.

Dry granulation techniques are generally also known in the art of pharmaceutical science. For example, paroxetine is conventionally admixed with dry excipients and compressed into large slugs or roller compacted into ribbon-like strands. The compacted material is then suitably milled to produce a free flowing powder which is then compressed into tablets.

Additional excipients may then be added and mixed with the free flowing powder before being compressed into tablets.

Examples of excipients include calcium phosphate, microcrystalline cellulose, sodium starch glycollate and magnesium stearate which may be admixed in appropriate ratios.

It should be appreciated that particularly good results are obtained when microcrystalline cellulose is absent from the formulation, this is surprising as tablets formulated in the absence of microcrystalline cellulose are often prone to breaking up during manufacture or storage.

The paroxetine/excipient mixture may be compressed into an appropriate tablet shape. Preferred shapes include a pentagonal circumcircle, oval, round bi-convex or a tilt-tablet such as those described in US Patent 4,493,822.

Paroxetine when incorporated into the above-mentioned tablets is suitably, present as the hydrochloride hemi-hydrate form which may be prepared according to the procedures outlined in US Patent 4,721,723.

The amount of paroxetine present in the above-mentioned tablets is in the range of 10 to 100 mg of paroxetine as measured in terms of the "free base".

Particularly preferred amounts include 10 mg, 20 mg, 30 mg, 40 mg and 50 mg of paroxetine as measured in terms of the "free base". Particularly preferred amounts include 20 mg, 30 mg and 40 mg of paroxetine as measured in terms of the "free base".

Suitable procedures for preparing paroxetine include those mentioned in US Patents 4,009,196, 4,902,801, 4,861,893 and 5,039,803 and PCT/GB 93/00721.

It has been mentioned that paroxetine has particular utility in the treatment of depression, paroxetine may also be used in the treatment of mixed anxiety and depression, obsessive compulsive disorders, panic, pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia and the depression arising from pre-menstrual tension and adolescence.

The present invention therefore also provides a method of treating or preventing any of the above disorders which comprises administering an effective or

prophylactic amount to a sufferer in need thereof of paroxetine which is formulated into a tablet using a process in which water is absent.

The present invention further provides a pharmaceutical composition comprising paroxetine which is formulated into a tablet using a process in which water is absent for use in treating or preventing of the above disorders.

The present invention further provides the use of paroxetine which is formulated into a tablet using a process in which water is absent in the manufacture of a medicament for treating or preventing the above disorders.

The following examples illustrate the present invention:

10

### Example 1

INGREDIENTS	20 mg Tablet	30mg Tablet
Paroxetine hydrochloride hemihydrate	22.67 mg	34.0 mg
Dicalcium Phosphate (DCP)	83.34 mg	125.0 mg
Microcrystalline Cellulose	50.67 mg	76.0 mg
Sodium Starch Glycollate	8.34 mg	12.5 mg
Magnesium Stearate	1.67 mg	2.5 mg
<b>Tablet Weight</b>	<b>166.7 mg</b>	<b>250.0 mg</b>

15 Commercial source of the ingredients

- Dicalcium Phosphate Dihydrate Emcompress or Ditab\*
- Microcrystalline Cellulose Avicel PH 102\*
- Sodium Starch Glycollate Explotab.\*

20

\* Tradenames

**Method**

1. Pass DCP through a screen and weigh it into a Planetary mixer.
- 5 2. Add 30 mesh Paroxetine to the bowl.
3. Add 20 mesh Avicel and Explotab and mix all the powders for 10 minutes.
4. Add magnesium Stearate and mix for 5 minutes.

10

**Tablet into Pentagonal Tablets using the following punches:**

30 mg Tablet	9.5 mm	Circumcircle
15 20 mg Tablet	8.25 mm	Circumcircle

The tablets are made satisfactorily on a single punch or a Rotary press.

**Example 2**

<b>INGREDIENTS</b>	<b>10 mg Tablet</b>	<b>20 mg Tablet</b>	<b>30mg Tablet</b>
Paroxetine hydrochloride hemihydrate	11.40 mg	22.80 mg	34.20 mg
Sodium Starch Glycollate	2.98 mg	5.95 mg	8.93 mg
Granular Dicalcium Phosphate (DITAB) or Dicafos	158.88 mg	317.75 mg	476.63 mg
Magnesium Stearate	1.75 mg	3.50 mg	5.25 mg
<b>Tablet Weight</b>	<b>175.00 mg</b>	<b>350.00 mg</b>	<b>525.00 mg</b>

**5 Method**

1. Paroxetine, Sodium Starch Glycollate and Dicalcium Phosphate Dihydrate are screened and mixed together in a suitable mixer.  
(Planetary, Cuble or High Energy Shear mixer.)
- 10  
2. Add Magnesium Stearate and compress it into a tablet using a single punch or Rotary Tablet machine.

**Claims**

1. Paroxetine which is formulated into tablets using a formulation process in which water is absent.
- 5 2. A formulation process according to claim 1 which is a dry direct compression of paroxetine followed by compression into tablets or a dry granulation of paroxetine followed by compression into tablets.
- 10 3. A formulation process according to claim 1 or 2 in which paroxetine is admixed with dry excipients.
4. A formulation process according to claim 3 in which the paroxetine admixed with dry excipients is compressed into large slugs or roller compacted into ribbon-like strands.
- 15 5. A formulation process according to claim 4 in which the compressed or compacted material is milled to produce a free flowing powder and compressed into tablets.
- 20 6. A formulation process according to claim 3, 4 or 5 in which the excipients are selected from calcium phosphate, microcrystalline cellulose, sodium starch glycollate and magnesium stearate which may be admixed in appropriate ratios.
- 25 7. A formulation process according to claim 3, 4, or 5 in which microcrystalline cellulose is absent from the formulation.
8. A formulation process according to claim 5 in which the tablet is compressed into a pentagonal circumcircle, oval, round bi-convex, or tilt-tablet shape.
- 30 9. A formulation process according to any one of claims 1 to 8 in which paroxetine is in the form of the hydrochloride hemi-hydrate.
- 35 10. A formulation comprising direct compressed paroxetine admixed with any excipients in the form of a tablet.
11. A formulation comprising dry granulated and compressed paroxetine admixed with excipients in the form of a tablet.
- 40 12. A formulation according to claim 10 or 11 in which the excipients are selected from calcium phosphate, microcrystalline cellulose, sodium starch glycollate and magnesium stearate which may be admixed in appropriate ratios.

13. A formulation according to claim 10 or 11 in which the microcrystalline cellulose is absent.

5        14. A formulation according to any one of claims 10 to 13 in which the tablet is compressed into a pentagonal circumcircle, oral, round bi-convex or tilt-tablet shape.

15. A formulation according to any one of claims 10 to 14 in which the paroxetine is in the form of the hydrochloride hemi-hydrate.

## INTERNATIONAL SEARCH REPORT

Internal Application No  
PCT/EP 94/04164

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K31/445 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used) °

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,92 09281 (BEECHAM GROUP PLC) 11 June 1992 see claims see example 1 ----	1-15
A	EP,A,0 269 303 (A/S FERROSAN) 1 June 1988 see claims see page 2, line 24 - line 50 ----	1-15
A	EP,A,0 223 403 (BEECHAM GROUP PLC) 27 May 1987 see claims 1,4,5 see page 7, line 42 - line 55 ----	1-15
A	EP,A,0 188 081 (A/S FERROSAN) 23 July 1986 see claims see page 2, line 21 - line 24 -----	1-15

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## ° Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- '&' document member of the same patent family

Date of the actual completion of the international search

7 April 1995

Date of mailing of the international search report

21.04.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl  
Fax: (+31-70) 340-3016

Authorized officer

Scarpioni, U

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Internat	Application No
PCT/EP	94/04164

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9209281	11-06-92	AU-A-	8915391	25-06-92
		CA-A-	2096853	25-05-92
		EP-A-	0558679	08-09-93
		JP-T-	6502854	31-03-94
		US-A-	5371092	06-12-94
-----				
EP-A-0269303	01-06-88	AU-B-	601237	06-09-90
		AU-A-	8091787	12-05-88
		DE-A-	3786893	09-09-93
		DE-T-	3786893	03-03-94
		ES-T-	2058125	01-11-94
		IE-B-	59941	04-05-94
		JP-A-	63211228	02-09-88
		US-A-	4804669	14-02-89
-----				
EP-A-0223403	27-05-87	AU-B-	593295	08-02-90
		AU-A-	6433286	30-04-87
		CZ-A-	9103910	19-01-94
		DE-A-	3688827	09-09-93
		DE-T-	3688827	31-03-94
		ES-T-	2058061	01-11-94
		IE-B-	59901	20-04-94
		JP-B-	6047587	22-06-94
		JP-A-	62129280	11-06-87
		US-A-	4721723	26-01-88
-----				
EP-A-0188081	23-07-86	AU-B-	580820	02-02-89
		AU-A-	5074985	12-06-86
		DE-A-	3585607	16-04-92
		JP-C-	1881453	21-10-94
		JP-A-	61148121	05-07-86
		US-A-	4745122	17-05-88
-----				